| Microorganism |
|
|
|
| Antimicrobial |
 |
|
Reference |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.06 |
0.03 － 0.06 |
AC98-6446 |
175 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.06 |
0.03 － 0.06 |
Sanfetrinem |
317 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.06 |
0.03 － >32 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
448 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.12 |
0.008 － 0.12 |
Sitafloxacin |
130 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.12 |
0.008 － 1 |
Gemifloxacin |
268 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.12 |
0.03 － 0.5 |
Moxifloxacin (BAY 12-8039, Avelox) |
1060 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.12 |
0.08 － 0.12 |
Sitafloxacin |
443 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.25 |
0.015 － 1 |
ACH-702 |
1276 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.26 |
≤0.03 － 1 |
Imipenem |
371 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
0.5 |
0.015 － 1 |
Imipenem |
248 |
| Staphylococcus aureus (methicillin-susceptible) |
0.03 |
2 |
≤0.016 － 4 |
Moxifloxacin (BAY 12-8039, Avelox) |
207 |
| Staphylococcus aureus (methicillin-susceptible) |
0.032 |
0.032 |
0.016 － 0.032 |
Imipenem |
952 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.06 |
0.008 － 2 |
Garenoxacin (T-3811, BMS-284756) |
1111 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.06 |
≤0.015 － 0.125 |
Dalbavancin |
72 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.06 |
0.015 － 4 |
Moxifloxacin (BAY 12-8039, Avelox) |
12 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.015 － 2 |
Moxifloxacin (BAY 12-8039, Avelox) |
268 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.015 － >128 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
948 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.016 － 0.12 |
Retapamulin |
120 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.03 － 0.25 |
DK-507k |
443 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.03 － 0.25 |
DK-507k |
130 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.03 － 8 |
HMR 3004 (RU 64004) |
448 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.06 － 0.12 |
Levofloxacin (Levaquin, Quixin) |
16 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
≤0.06 － 0.25 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
396 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.06 － 0.25 |
Moxifloxacin (BAY 12-8039, Avelox) |
130 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.12 |
0.06 － 0.25 |
Moxifloxacin (BAY 12-8039, Avelox) |
443 |
| Staphylococcus aureus (Methicillin-susceptible) |
0.06 |
0.125 |
0.016 － 0.125 |
Retapamulin |
596 |
| Staphylococcus aureus (Methicillin-susceptible) |
0.06 |
0.125 |
0.03 － 0.125 |
Retapamulin |
596 |
| Staphylococcus aureus (methicillin-susceptible) |
0.06 |
0.125 |
0.06 － 0.125 |
Faropenem |
317 |